Brief: Basilea: Annouces Sale Of Preclinical Oncology Program To Twentyeight-Seven Therapeutics

Basilea Pharmaceutica AG, Allschwil

02/11/2022 06:18

Nov 2 (Reuters) - Basilea Pharmaceutica Ag  BSLN.S :
    * BASILEA ANNOUNCES SALE OF PRECLINICAL ONCOLOGY PROGRAM TO
TWENTYEIGHT-SEVEN THERAPEUTICS
    * SALE OF BASILEA'S NOVEL PRECLINICAL CLK KINASE INHIBITORS
    * TOTAL PAYMENTS OF UP TO CHF 354 MILLION
    * THIRD ONCOLOGY TRANSACTION AS PART OF BASILEA'S STRATEGIC
REFOCUSING ON ANTI-INFECTIVES
    * UNDER TERMS OF AGREEMENT, BASILEA WILL RECEIVE AN UPFRONT
PAYMENT OF CHF 1 MILLION AND POTENTIAL NEAR-TERM MILESTONE
PAYMENTS OF CHF 2 MILLION
    * BASILEA IS ELIGIBLE TO RECEIVE FURTHER PAYMENTS OF UP TO
CHF 351
MILLION UPON ACHIEVEMENT OF PREDEFINED DEVELOPMENT, REGULATORY
AND SALES MILESTONES

Further company coverage:  BSLN.S 
 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))